At the time of the current COVID-19 pandemic, on a daily basis, we encountered patients suffering from various manifestations of this infection. The most common are respiratory symptoms. Many of the patients require acute hospital care, and a smaller group of them are hospitalized in intensive care units. A subset of these critically ill patients demonstrates clinically remarkable hypercoagulability and thus a predisposition to venous and arterial thromboembolism, manifested by thrombotic events ranging from acute pulmonary embolism and splanchnic vascular ischemia to extremity ischemia. The article describes a case of a patient with COVID-19 pneumonia complicated by massive bleeding into the gastrointestinal tract due to ischemic enterocolitis in connection with COVID-19 infection.
Summary: Disorders of the pelvic floor and anorectal dysfunction are a major cause of discomfort for many women. As a result of shyness and embarrassment, women come for medical examination after a longer period of difficulties, mostly for progressive disorder of defecation and continence. Despite the low morbidity, anorectal dysfunctions have a very significant impact on patient’s quality of life and therefore diagnosis and subsequent treatment should be aimed at every possible cause. Gastroenterological examination can play an important part In primary detection, but also in the multidisciplinary diagnostic process of pelvic floor pathology. Likewise, coloproctology is an integral part of the diagnostic-therapeutic algorithm of pelvic dysfunctions. The aim of the article is to provide information on the pathophysiology, diagnosis and treatment of anorectal disorders from the perspective of coloproctology. Anorectal dysfunctions are a multidisciplinary problem, therefore, to achieve good treatment results, the cooperation of different specializations is essential. Key words: anorectal dysfunction – defecation – prolapse – rectocele – incontinence – rectopexy
klinika LF MU a FN u sv. Anny v Brně 2 Gastroenterlogické oddělení FN u sv. Anny v Brně 3 Nemocniční lékárna FN u sv. Anny v Brně V tomto článku jsou komplexně popsány různé způsoby léčby hemoroidů od ambulantní péče po operační řešení včetně aktuálních možností staplerové techniky. Indikace jednotlivých výkonů je rozebrána na podkladě klinického vyšetření a "stagingu" onemocnění. Autoři se snaží analyzovat jednotlivé metody léčby a diferencovat jejich využití.
Background: Colour marking of indicated deposits is an innovative, accurate and gentle method that allows subsequent wedge resection of the marked tissue using a mini-invasive, video-assisted thoracoscopic (VATS) method with all its benefits. One of the expected benefits of this clinical trial is the introduction and optimization of the evaluated method into routine management in the diagnosis and treatment of focal lung diseases. The BLUEPAT clinical trial aims to evaluate the method of colour marking of subpleural deposited small lung deposits with the subsequent performance of VATS wedge resection in surgical practice.Methods: The BLUEPAT clinical trial is a prospective, monocentric, open-label, randomized study that will include 72 subjects with subpleural deposited lesions with the need for additional histological diagnostics to optimize subsequent treatment. These patients will be randomized into 2 groups in a 1:1 ratio. The first group will undergo VATS wedge resection of lung deposits marked with patent blue and contrast agent iohexol under CT-guided control. The second group will undergo VATS resection without prior colour coding of the lung deposits. The feasibility and safety of both methods will be assessed based on the evaluation of the parameters of the primary and secondary objectives of the study. The safety of the methods will be monitored by recording all related adverse events. The patients will participate in the clinical trial for 30 days.Discussion: The BLUEPAT clinical trial provides a unique evaluation of this innovative approach in the diagnosis and treatment of focal lung diseases. Clinical trials support the patent blue dyeing diagnostic procedures for the detection of breast cancer.Trial registration: EudraCT Number 2021-001122-22, Registered on 20.04.2021, https://www.sukl.eu/modules/evaluation/detail.php?id=51957&lang=2
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.